Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones06:42

Eli Lilly's potential new weight-loss drug Foundayo had positive results in a Phase 3 trial.

Foundayo, which is being studied as a treatment for obesity and Type-2 diabetes, demonstrated a non-inferior risk of major adverse cardiovascular events, compared with the alternative treatment insulin glargine.

Patients treated with the drug also had improved weight and other key measures of cardiometabolic health compared with insulin glargine, the company said.

The risk of cardiovascular death, heart attack, stroke or hospitalization for unstable sudden chest pain was 16% lower for Foundayo versus insulin glargine.

At week 52, participants treated with Foundayo experienced reductions in waist circumference by 7 centimeters and lower systolic blood pressure.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment